LU91655I2 - Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®) - Google Patents

Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)

Info

Publication number
LU91655I2
LU91655I2 LU91655C LU91655C LU91655I2 LU 91655 I2 LU91655 I2 LU 91655I2 LU 91655 C LU91655 C LU 91655C LU 91655 C LU91655 C LU 91655C LU 91655 I2 LU91655 I2 LU 91655I2
Authority
LU
Luxembourg
Prior art keywords
elonva
pharmaceutically acceptable
acceptable derivatives
corifollitropin alfa
corifollitropin
Prior art date
Application number
LU91655C
Other languages
English (en)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of LU91655I2 publication Critical patent/LU91655I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU91655C 1997-01-15 2010-02-24 Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®) LU91655I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200099 1997-01-15
EP98200068A EP0853945B1 (fr) 1997-01-15 1998-01-13 Formulations liquides contenant une gonadotropine

Publications (1)

Publication Number Publication Date
LU91655I2 true LU91655I2 (fr) 2010-04-26

Family

ID=8227932

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91655C LU91655I2 (fr) 1997-01-15 2010-02-24 Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)

Country Status (29)

Country Link
US (1) US5929028A (fr)
EP (2) EP0853945B1 (fr)
JP (1) JP4353549B2 (fr)
KR (1) KR100498531B1 (fr)
CN (1) CN1165341C (fr)
AR (1) AR011410A1 (fr)
AT (1) ATE237348T1 (fr)
AU (1) AU736339B2 (fr)
BR (1) BR9800323B1 (fr)
CA (1) CA2226803A1 (fr)
CZ (1) CZ297419B6 (fr)
DE (2) DE69813322T2 (fr)
DK (1) DK0853945T3 (fr)
ES (1) ES2196474T3 (fr)
FR (1) FR10C0024I2 (fr)
HU (1) HU227154B1 (fr)
ID (1) ID19499A (fr)
IL (1) IL122732A0 (fr)
LU (1) LU91655I2 (fr)
MX (1) MX9800438A (fr)
NO (3) NO322509B1 (fr)
NZ (1) NZ329572A (fr)
PL (1) PL190103B1 (fr)
PT (1) PT853945E (fr)
RU (1) RU2203086C2 (fr)
SA (1) SA98181124B1 (fr)
TR (1) TR199800062A2 (fr)
TW (1) TW518235B (fr)
ZA (1) ZA9883B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
NZ516507A (en) * 1999-07-12 2004-02-27 Grandis Biotech Gmbh Growth hormone formulations that are resistant to crystallisation
IL151309A0 (en) * 2000-02-22 2003-04-10 Applied Research Systems Purification of lh and pharmaceutical compositions containing it
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
AU2007200662A1 (en) * 2001-08-30 2007-03-08 Kirin-Amgen, Inc. L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1346843A1 (fr) * 2002-03-22 2003-09-24 Fuji Photo Film Co., Ltd. Procédé de formation d'images
EP1610803B8 (fr) 2003-03-04 2011-09-14 AspenBio Pharma, Inc. LH pour utilisation pour maintenir une ou plusieurs grossesses en induisant la formation du corps jaune secondaire.
ZA200507287B (en) * 2003-04-02 2007-03-28 Ares Trading Sa Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
MXPA05010635A (es) 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2004112826A1 (fr) * 2003-06-20 2004-12-29 Ares Trading Sa Formulations lyophilisees a base de fsh/lh
JP4412989B2 (ja) * 2003-12-15 2010-02-10 株式会社日立製作所 複数の記憶システムを有するデータ処理システム
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
TWI369401B (en) 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007056851A1 (fr) * 2005-11-17 2007-05-24 Mount Sinai Hospital Compositions et procedes visant a ameliorer les agents inducteurs de l'ovulation
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20090261690A1 (en) * 2006-09-25 2009-10-22 Tomoaki Mashimo Ultrasonic wave handling device and a microscopic in-tube inspection system
KR20080106636A (ko) * 2007-06-04 2008-12-09 동아제약주식회사 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
WO2009002521A2 (fr) * 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison spécifiques vis-à-vis du facteur de croissance des hépatocytes
KR101522217B1 (ko) 2007-06-28 2015-05-21 바이오제너릭스 게엠베하 Ｆｓｈ 제조 세포 클론
NZ583991A (en) * 2007-11-01 2012-02-24 Merck Serono Sa Luteinizing hormone liquid formulations
BRPI0908887B8 (pt) * 2008-02-08 2021-05-25 Biogenerix Ag composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
CA2742659C (fr) 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Composition aqueuse contenant de l'hormone folliculostimulante
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2325194A1 (fr) 2009-11-24 2011-05-25 Glycotope GmbH Processus de purification de glycoprotéines
EP2417982A1 (fr) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisation de gonadotrophines
WO2012127501A2 (fr) * 2011-03-11 2012-09-27 Sanzyme Limited Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne
WO2012127500A2 (fr) * 2011-03-11 2012-09-27 Sanzyme Limited Composition pour la spermatogenèse
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
CN103930134B (zh) 2011-07-18 2016-12-21 阿茨生物股份有限公司 长效促黄体激素(lh)化合物
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
BR112015008753A2 (pt) 2012-10-18 2017-07-04 Neuralight Hd Llc tratamento de depressão e ptsd
ES2882890T3 (es) 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
WO2014159813A1 (fr) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
HK1223559A1 (zh) 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
JP6646662B2 (ja) * 2014-10-21 2020-02-14 ヘキシマ リミテッド 治療方法
WO2016092550A2 (fr) 2014-12-10 2016-06-16 Opko Biologics Ltd. Méthodes de production de polypeptides modifiés par des ctp à action prolongée
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3988113A1 (fr) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Facteurs de coagulation à action prolongée et ses procédés de production
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
EP3969026A1 (fr) 2019-05-16 2022-03-23 Ceva Santé Animale Compositions et méthodes pour augmenter la performance de reproduction chez des mammifères non humains à l'aide d'une hormone lutéinisante recombinante
CN114404575A (zh) * 2020-12-07 2022-04-29 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
CN117783545B (zh) * 2023-12-28 2026-03-06 深圳市新产业生物医学工程股份有限公司 经封闭剂封闭的软质材料、容器、液态校准品及检测试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357934A (en) * 1980-07-23 1982-11-09 The Curators Of The University Of Missouri Method of treating male infertility
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
AU648020B2 (en) * 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
DK0639202T3 (da) * 1992-04-30 1999-08-09 Cor Therapeutics Inc Stabil polypeptidsammensætning
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
RU2062619C1 (ru) * 1994-02-08 1996-06-27 Курский сельскохозяйственный институт им.проф.И.И.Иванова Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных
AU707796B2 (en) * 1995-03-21 1999-07-22 Merck Serono Sa HCG liquid formulations

Also Published As

Publication number Publication date
AU736339B2 (en) 2001-07-26
EP0853945A1 (fr) 1998-07-22
ZA9883B (en) 1998-07-08
FR10C0024I2 (fr) 2011-04-01
NO2021001I1 (no) 2021-01-12
MX9800438A (es) 1998-11-30
PL324279A1 (en) 1998-07-20
CA2226803A1 (fr) 1998-07-15
KR19980070493A (ko) 1998-10-26
TW518235B (en) 2003-01-21
PL190103B1 (pl) 2005-10-31
IL122732A0 (en) 1998-08-16
DE69813322D1 (de) 2003-05-22
TR199800062A2 (xx) 1998-08-21
NO980177L (no) 1998-07-16
ATE237348T1 (de) 2003-05-15
BR9800323B1 (pt) 2011-04-19
DK0853945T3 (da) 2003-08-04
EP1285665A1 (fr) 2003-02-26
ES2196474T3 (es) 2003-12-16
CZ297419B6 (cs) 2006-12-13
HUP9800056A3 (en) 2001-01-29
HU227154B1 (en) 2010-08-30
AU5205998A (en) 1998-07-23
HK1010150A1 (en) 1999-06-17
EP0853945B1 (fr) 2003-04-16
NO322509B1 (no) 2006-10-16
FR10C0024I1 (fr) 2010-05-21
ID19499A (id) 1998-07-16
DE69813322T2 (de) 2004-02-19
NO2010013I1 (no) 2010-06-07
PT853945E (pt) 2003-08-29
HU9800056D0 (en) 1998-03-02
JP4353549B2 (ja) 2009-10-28
NZ329572A (en) 1999-05-28
SA98181124B1 (ar) 2006-07-10
BR9800323A (pt) 1999-06-29
AR011410A1 (es) 2000-08-16
US5929028A (en) 1999-07-27
DE122010000011I1 (de) 2010-07-08
HUP9800056A2 (hu) 1998-08-28
NO2010013I2 (no) 2015-05-18
NO980177D0 (no) 1998-01-14
CN1191139A (zh) 1998-08-26
CZ13598A3 (cs) 1998-08-12
CN1165341C (zh) 2004-09-08
KR100498531B1 (ko) 2005-09-30
JPH10203997A (ja) 1998-08-04
RU2203086C2 (ru) 2003-04-27

Similar Documents

Publication Publication Date Title
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
FI952033A7 (fi) Farmakologisesti aktiiviset pyrrolopyrimidiinijohdannaiset
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
DE69633991T2 (de) CMDA-Basisstaionssender
DK1005446T3 (da) N-aroylphenylalaninderivater
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
LU91849I2 (fr) Cimicoxib et ses dérivés pharmaceutiquement acceptables - CIMALGEX®.
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
PL337773A1 (en) Derivatives of benzimidazoles
DE69817186D1 (de) Diaminorhodamin-derivate
DE59707194D1 (de) Direkttablettierhilfsmittel
DE69623090D1 (de) Bett
DE19980536D2 (de) Vinylen- und Ethylverbindungen